Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5126]

Biomarkers of pembrolizumab response in head and neck cancer

Dr Tanguy Seiwert - The University of Chicago Medicine, Chicago, USA

Biomarkers of pembrolizumab response in head and neck cancer ( Dr Tanguy Seiwert - The University of Chicago Medicine, Chicago, USA )

Phase I taselisib results and a cell-free DNA assay

Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA

Phase I taselisib results and a cell-free DNA assay ( Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA )

Safety indications in mouse models treated with full doses of MEK inhibitors...

Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York...

Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099 ( Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical, New York, USA )

A variety of approaches to measure the efficacy of PARP inhibitors

Dr Elisabetta Leo - AstraZeneca, Cambridge, UK

A variety of approaches to measure the efficacy of PARP inhibitors ( Dr Elisabetta Leo - AstraZeneca, Cambridge, UK )

Development and clinical indications of PARP inhibitors

Dr Mark O'Connor - AstraZeneca, Cambridge, UK

Development and clinical indications of PARP inhibitors ( Dr Mark O'Connor - AstraZeneca, Cambridge, UK )

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL

Dr Susan Galbraith - AstraZeneca, Cambridge, UK

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL ( Dr Susan Galbraith - AstraZeneca, Cambridge, UK )

Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy

Dr Theodore Johnson - Georgia Cancer Center, Augusta, USA

Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy ( Dr Theodore Johnson - Georgia Cancer Center, Augusta, USA )

Impact of microbiome on head and neck cancers

Dr Young Jun Kim - Vanderbilt-Ingram Cancer Center, Nashville, USA

Impact of microbiome on head and neck cancers ( Dr Young Jun Kim - Vanderbilt-Ingram Cancer Center, Nashville, USA )

First-in-human trial results of RET targeted BLU-667

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

First-in-human trial results of RET targeted BLU-667 ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

Treating RET alterations with novel therapy BLU-667

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

Treating RET alterations with novel therapy BLU-667 ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

AKT inhibitors in research and application

Dr Brian Schwartz - ArQule, Burlington, USA

AKT inhibitors in research and application ( Dr Brian Schwartz - ArQule, Burlington, USA )

Tandem duplications in triple negative breast cancer

Dr Ed Liu - The Jackson Laboratory, Bar Harbor, USA

Tandem duplications in triple negative breast cancer ( Dr Ed Liu - The Jackson Laboratory, Bar Harbor, USA )

More from ecancer